Correction of peripheral lysosomal accumulation in mice with aspartylglucosaminuria by bone marrow transplantation

Experimental Hematology

Volumn 27, Issue 9, 1999, Pages 1467-1474

  Laine, Minna ^a   Richter, Johan ^b   Fahlman, Cecilia ^b   Rapola, Juhani ^c   Renlund, Martin ^d   Peltonen, Leena ^a   Karlsson, Stefan ^b   Jalanko, Anu ^a  

^a NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^b LUND UNIVERSITY   (Sweden)

^c UNIVERSITY OF HELSINKI   (Finland)

^d UNIVERSITY OF HELSINKI AND HELSINKI UNIVERSITY HOSPITAL   (Finland)

Author keywords

Aspartylglucosaminuria; Bone marrow transplantation; Lysosomal storage; Mouse model

Indexed keywords

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASPARTYLGLYCOSAMINURIA; BONE MARROW TRANSPLANTATION; BRAIN; ELECTRON MICROSCOPY; ENZYME ACTIVITY; ENZYME SUBSTRATE; GENE; IMMUNOBLOTTING; KIDNEY; LIVER; LYSOSOME; MICROSCOPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPLEEN; THIN LAYER CHROMATOGRAPHY; URINARY EXCRETION;

ACETYLGLUCOSAMINE; AMINO ACID METABOLISM, INBORN ERRORS; ANIMALS; ASPARTYLGLUCOSYLAMINASE; BONE MARROW TRANSPLANTATION; BRAIN; HUMANS; KIDNEY; LIVER; LYSOSOMAL STORAGE DISEASES; LYSOSOMES; MENTAL RETARDATION; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NERVE TISSUE PROTEINS; ORGAN SPECIFICITY; POLYMERASE CHAIN REACTION; RADIATION CHIMERA; SPECIFIC PATHOGEN-FREE ORGANISMS; SPLEEN; VACUOLES;

ANIMALIA;

EID: 0032845933     PISSN: 0301472X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0301-472X(99)00075-2     Document Type: Article

References (31)

1. Aula P., Autio S., Raivio K., Rapola J. Aspartylglucosaminuria. In. Genetic errors of glycoprotein metabolism:1982;123 Springer-Verlag, Berlin.
2. Ikonen E., Julkunen I., Tollersrud O.-K., Kalkkinen N., Peltonen L. Lysosomal aspartylglucosaminidase is processed to the active subunit complex in the endoplasmic reticulum. EMBO J. 12:1993;295.
3. Oinonen C., Tikkanen R., Rouvinen J., Peltonen L. Three-dimensional structure of human lysosomal aspartylglucosaminidase. Nature Struct Biol. 2:1995;1102.
4. Tikkanen R., Riikonen A., Oinonen C., Rouvinen J., Peltonen L. Functional analyses of active site residues of human lysosomal aspartylglucosaminidase. implications for catalytic mechanism and autocatalytic activation EMBO J. 15:1996;2954.
5. Riikonen A., Rouvinen J., Tikkanen R., Julkunen I., Peltonen L., Jalanko A. Primary folding of aspartylglucosaminidase. Significance of disulfide bridges and evidence of early multimerization J Biol Chem. 271:1996;21340.
6. Tikkanen R., Peltola M., Oinonen C., Rouvinen J., Peltonen L. Several co-operating binding sites mediate the interaction of a lysosomal enzyme with phosphotransferase. EMBO J. 16:1997;6684.
7. Saarela J., Laine M., Tikkanen R., Oinonen C., Jalanko A., Rouvinen J., Peltonen L. Activation and oligomerization of aspartylglucosaminidase. J Biol Chem. 273:1998;25320.
8. Jalanko A., Tenhunen K., McKinney C.E., LaMarca M.E., Rapola J., Autti T., Joensuu R., Manninen T., Sipilä I., Ikonen S., Riekkinen P. Jr., Ginns E.I., Peltonen L. Mice with aspartylglucosaminuria mutation similar to humans replicate the pathophysiology in patients. Hum Mol Genet. 7:1998;265.
9. Tenhunen K., Uusitalo A., Autti T., Joensuu R., Kettunen M., Kauppinen R.A., Ikonen S., LaMarca M., Haltia M., Ginns E.I., Jalanko A., Peltonen L. Monitoring the CNS pathology in aspartylglucosaminuria mice. J Neuropath Exp Neur. 57:1998;1154.
10. Arvio M. Life with aspartylglucosaminuria (Ph.D. thesis). 1993;University of Helsinki, Helsinki.
11. Peltola M., Kyttälä A., Heinonen O., Rapola J., Paunio T., Revah F., Peltonen L., Jalanko A. Adenovirus-mediated gene transfer results in decreased lysosomal storage in brain and total correction in liver of aspartylglucosaminuria (AGU) mouse. Gene Therapy. 5:1998;1314.
12. Enomaa N., Danos O., Peltonen L., Jalanko A. In vitro correction of deficient enzyme activity in a lysosomal storage disease, aspartylglucosaminuria. Human Gene Therapy. 6:1995;723.
13. Kyttälä A., Heinonen O., Peltonen L., Jalanko A. Expression and endocytosis of lysosomal aspartylglucosaminidase in mouse primary neurons. J Neurosci. 19:1998;7750.
14. Autti T., Santavuori P., Raininko R., Renlund M., Rapola J., Saarinen-Pihkala U. Bone-marrow transplantation in aspartylglucosaminuria. Lancet. 349:1997;1366.
15. Peltola M., Tikkanen R., Peltonen L., Jalanko A. Ser72Pro active site disease mutation in human lysosomal aspartylglucosaminidase. abnormal intracellular processing and evidence for extracellular activation Hum Mol Genet. 5:1996;737.
16. Renlund M., Aula P., Raivio K.O., Autio S., Sainio K., Rapola J., Koskela S.-L. Salla disease. a new lysosomal storage disorder with disturbed sialic acid metabolism Neurology. 33:1983;57.
17. Hoogerbrugge P.M., Brouwer O.F., Bordigoni P., Ringden O., Kapaun P., Ortega J.J., O'Meara A., Cornu G., Souillet G., Frappaz D., Blanche S., Fishcer A. Allogeneic bone marrow transplantation for lysosomal storage diseases. Lancet. 345:1995;1398.
18. Walkley S.U., Dobrenis K. Bone marrow transplantation for lysosomal diseases. Lancet. 345:1995;1382.
19. Walkley S.U., Thrall M.A., Dobrenis K., Huang M., March P.A., Siegel D.A., Wurzelmann S. Bone marrow transplantation corrects the enzyme defect in neurons of the central nervous system in a lysosomal storage disease. Proc Natl Acad Sci U S A. 91:1994;2970.
20. Birkenmeier E.H., Barker J.E., Vogler C.A., Kyle J.W., Sly W.S., Gwynn B., Levy B., Pegros C. Increased life span and correction of metabolic defects in murine mucopolysaccharidosis type VII after syngeneic bone marrow transplantation. Blood. 78:1991;3081.
21. Sands M.S., Barker J.E., Vogler C., Levy B., Gwynn B., Galvin N., Sly W., Birkenmeier E. Treatment of murine mucopolysaccharidosis type VII by syngeneic bone marrow transplantation in neonates. Lab Invest. 68:1993;676.
22. Taylor R.M., Farrow B.R., Stewart G.J. Amelioration of the clinical course following bone marrow transplantation in fucosidase-deficient dog. Am J Med Genet. 42:1992;628.
23. Hoogerbrugge P.M., Poorthuis B.J.H.M., Romme A.E., van de Kamp J.J.P., Wagemaker G., van Bekkum D.W. Effect of bone marrow transplantation on enzyme levels and clinical course in the neurologically affected twitcher mouse. J Clin Invest. 81:1988;1790.
24. Hoogerbrugge P.M., Suzuki K., Suzuki K., Poorthuis B.J., Kobayashi T., Wagemaker G., van Bekkum D.W. Donor-derived cells in the central nervous system of twitcher mice after bone marrow transplantation. Science. 239:1988;1035.
25. Kennedy D.W., Abkowitz J.L. Kinetics of central nervous system microglial and macrophage engraftment. analysis using a transgenic bone marrow transplantation model Blood. 90:1997;986.
26. Walkley SU, Thrall MA, Dobrenis K (1996) Targeting gene products to the brain and neurons using bone marrow transplantation: a cell-mediated delivery system for therapy of inherited metabolic human disease. In: Protocols for gene transfer in neuroscience: towards gene therapy of neurological disorders. Chichester, John Wiley & Sons, 275.
27. Norflus F., Tifft C.J., McDonald M.P., Goldstein G., Crawley J.N., Hoffmann A., Sandhoff K., Suzuki K., Proia R.L. Bone marrow transplantation prolongs life span and ameliorates neurologic manifestations in Sandhoff disease mice. J Clin Invest. 101:1998;1881.
28. Boothe A.D., Weintroub H., Pentchev P.G., Jones J., Butler J., Barry J.E., Neumeyer B., Stivers J.A., Brady R.O. A lysosomal storage disorder in the Balb/c mouse. bone marrow transplantation Vet Pathol. 21:1984;432.
29. Haltia M., Palo J., Autio S. Aspartylglucosaminuria. a generalized storage disease. Morphological and histochemical studies Acta Neuropathol (Berl). 31:1975;243.
30. Autti T., Raininko R., Haltia M., Lauronen L., Vanhanen S.-L., Salonen O., Aronen H.J., Wirtavuori K., Santavuori P. Aspartylglucosaminuria. radiologic course of the disease with histopathologic correlation J Child Neurol. 12:1997;369.
31. Ioannou Y., Bishop D., Desnick R. Overexpression of human alpha-galactosidase A results in its intracellular aggregation, crystallization in lysosomes and selective secretion. J Cell Biol. 119:1992;1137.